These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9690377)

  • 1. p53 and follow-up of colorectal adenocarcinomas.
    Polge A; Bourgaux JF; Bancel E; Pignodel C; Boyer JC; Poirey S; de Bornier BM; Balmes JL; Bali JP
    Dig Dis Sci; 1998 Jul; 43(7):1434-42. PubMed ID: 9690377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
    Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
    Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.
    Hammel P; Boissier B; Chaumette MT; Piedbois P; Rotman N; Kouyoumdjian JC; Lubin R; Delchier JC; Soussi T
    Gut; 1997 Mar; 40(3):356-61. PubMed ID: 9135525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC; Lin JK; Lin TC; Liang WY
    Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer.
    Hammel P; Leroy-Viard K; Chaumette MT; Villaudy J; Falzone MC; Rouillard D; Hamelin R; Boissier B; Remvikos Y
    Int J Cancer; 1999 May; 81(5):712-8. PubMed ID: 10328221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas.
    Colomer A; Erill N; Verdú M; Roman R; Vidal A; Cordon-Cardo C; Puig X
    Appl Immunohistochem Mol Morphol; 2003 Jun; 11(2):130-7. PubMed ID: 12777996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum p53 antibody assay: evaluation in colorectal cancer].
    Hammel P; Soussi T
    Rev Med Interne; 2000 Feb; 21(2):167-73. PubMed ID: 10703073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas.
    Dix B; Robbins P; Carrello S; House A; Iacopetta B
    Br J Cancer; 1994 Oct; 70(4):585-90. PubMed ID: 7917901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas.
    Suwa H; Ohshio G; Okada N; Wang Z; Fukumoto M; Imamura T; Imamura M
    Gut; 1997 May; 40(5):647-53. PubMed ID: 9203945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of serum anti-P53 antibodies from patients with colorectal cancer in China using a combination of P53- and phage-ELISA: correlation to clinical parameters.
    Wu J; Qiu T; Pan P; Yu D; Ju Z; Qu X; Gao X; Mao C; Wang L
    Asian Pac J Cancer Prev; 2011; 12(11):2921-4. PubMed ID: 22393964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 Mutations are present in colorectal cancer with cytoplasmic p53 accumulation.
    Jansson A; Gentile M; Sun XF
    Int J Cancer; 2001 May; 92(3):338-41. PubMed ID: 11291068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas.
    Smith DR; Ji CY; Goh HS
    Br J Cancer; 1996 Jul; 74(2):216-23. PubMed ID: 8688324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
    Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
    Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection.
    Takeda A; Shimada H; Nakajima K; Yoshimura S; Suzuki T; Asano T; Ochiai T; Isono K
    Int J Clin Oncol; 2001 Feb; 6(1):45-9. PubMed ID: 11706527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers.
    Wang JY; Hsieh JS; Chang MY; Huang TJ; Chen FM; Cheng TL; Alexandersen K; Huang YS; Tzou WS; Lin SR
    World J Surg; 2004 Jul; 28(7):721-6. PubMed ID: 15185002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival.
    Shiota G; Ishida M; Noguchi N; Oyama K; Takano Y; Okubo M; Katayama S; Tomie Y; Harada K; Hori K; Ashida K; Kishimoto Y; Hosoda A; Suou T; Kanbe T; Tanaka K; Nosaka K; Tanida O; Kojo H; Miura K; Ito H; Kaibara N; Kawasaki H
    Dig Dis Sci; 2000 Jan; 45(1):122-8. PubMed ID: 10695624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.
    Lechpammer M; Lukac J; Lechpammer S; Kovacević D; Loda M; Kusić Z
    Int J Colorectal Dis; 2004 Mar; 19(2):114-20. PubMed ID: 14634775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.